Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jul 28;10(7):e0134493.
doi: 10.1371/journal.pone.0134493. eCollection 2015.

Patient-Derived Gastric Carcinoma Xenograft Mouse Models Faithfully Represent Human Tumor Molecular Diversity

Tianwei Zhang  1 , Lin Zhang  1 , Shuqiong Fan  1 , Meizhuo Zhang  2 , Haihua Fu  1 , Yuanjie Liu  1 , Xiaolu Yin  1 , Hao Chen  3 , Liang Xie  1 , Jingchuan Zhang  1 , Paul R Gavine  1 , Yi Gu  1 , Xingzhi Ni  3 , Xinying Su  1
Affiliations

Patient-Derived Gastric Carcinoma Xenograft Mouse Models Faithfully Represent Human Tumor Molecular Diversity

Tianwei Zhang et al. PLoS One. .

Abstract

Patient-derived cancer xenografts (PDCX) generally represent more reliable models of human disease in which to evaluate a potential drugs preclinical efficacy. However to date, only a few patient-derived gastric cancer xenograft (PDGCX) models have been reported. In this study, we aimed to establish additional PDGCX models and to evaluate whether these models accurately reflected the histological and genetic diversities of the corresponding patient tumors. By engrafting fresh patient gastric cancer (GC) tissues into immune-compromised mice (SCID and/or nude mice), thirty two PDGCX models were established. Histological features were assessed by a qualified pathologist based on H&E staining. Genomic comparison was performed for several biomarkers including ERBB1, ERBB2, ERBB3, FGFR2, MET and PTEN. These biomarkers were profiled to assess gene copy number by fluorescent in situ hybridization (FISH) and/or protein expression by immunohistochemistry (IHC). All 32 PDGCX models retained the histological features of the corresponding human tumors. Furthermore, among the 32 models, 78% (25/32) highly expressed ERBB1 (EGFR), 22% (7/32) were ERBB2 (HER2) positive, 78% (25/32) showed ERBB3 (HER3) high expression, 66% (21/32) lost PTEN expression, 3% (1/32) harbored FGFR2 amplification, 41% (13/32) were positive for MET expression and 16% (5/32) were MET gene amplified. Between the PDGCX models and their parental tumors, a high degree of similarity was observed for FGFR2 and MET gene amplification, and also for ERBB2 status (agreement rate = 94~100%; kappa value = 0.81~1). Protein expression of PTEN and MET also showed moderate agreement (agreement rate = 78%; kappa value = 0.46~0.56), while ERBB1 and ERBB3 expression showed slight agreement (agreement rate = 59~75%; kappa value = 0.18~0.19). ERBB2 positivity, FGFR2 or MET gene amplification was all maintained until passage 12 in mice. The stability of the molecular profiles observed across subsequent passages within the individual models provides confidence in the utility and translational significance of these models for in vivo testing of personalized therapies.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: This study is fully funded by AstraZeneca. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.

Figures

Fig 1
Fig 1. PDGCX models retain the histological features and genetic profiles of their parental tumors.
(A) shows comparison of histological subtypes of GC observed in primary tumors (a, b) and corresponding PDGCX models (c, d); (B) shows FGFR2, ERBB2 and MET gene amplification in primary tumors (F0) and corresponding PDGCX models. All target gene probes are labeled in red and CEP control probes are in green, nuclei are counterstained in blue by DAPI. (C) shows ERBB1 (+++), ERBB2 (+++), ERBB3 (+++), PTEN (-ve) and MET (+++) expression on primary tumors and corresponding PDGCX models.
Fig 2
Fig 2. Biomarker profiles of serial passages of PDGCX models.
Representative images of MET status (A), ERBB2 status (B) and FGFR2 gene amplification (C) on serial passages of PDGCX models by FISH or IHC are shown. All target gene probes for FISH are labeled in red and CEP control probes are in green, nuclei are counterstained in blue by DAPI.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–386. 10.1002/ijc.29210 - DOI - PubMed
    1. Power DG, Kelsen DP, Shah MA. Advanced gastric cancer—slow but steady progress. Cancer Treat Rev. 2010;36:384–392. 10.1016/j.ctrv.2010.01.005 - DOI - PubMed
    1. Asaoka Y, Ikenoue T, Koike K. New targeted therapies for gastric cancer. Expert Opin Investig Drugs. 2011;20:595–604. 10.1517/13543784.2011.566863 - DOI - PubMed
    1. de Mello RA, Marques AM, Araujo A. HER2 therapies and gastric cancer: a step forward. World J Gastroenterol. 2013;19:6165–6169. 10.3748/wjg.v19.i37.6165 - DOI - PMC - PubMed
    1. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–697. 10.1016/S0140-6736(10)61121-X - DOI - PubMed

Publication types

MeSH terms

Substances

Grants and funding

This study is fully funded by AstraZeneca. To clarify, AstraZeneca authors were fully involved in study design, data collection and analysis, decision to publish, or preparation of the manuscript.